C-Bridge Capital Leads $100M Round In Chinese Drug Start-Up Ascletis

C-Bridge Capital, a US$700 million-under-management healthcare private equity fund in China, has led a US$100 million new funding round in Chinese pharmaceutical start-up Ascletis, according to Chinese media reports.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY